skyebioscience.com - Total Nilai Perusahaan SKYE

Skye Bioscience, Inc. (SKYE) is a developer of synthetic cannabinoid-based drugs focusing on glaucoma therapy and weight management. The price action, where the indicator stands at -3.15, is based on the test results of the new CB1 molecule. Growth prospects are driven by entry into the metabolic drug segment and the probability of acquisition by market behemoths, provided there is strict control over medical research expenditures.

The development of innovative obesity treatments drives the high value of Skye Bioscience, Inc. (SKYE) intellectual assets. An analysis of the total enterprise value allows for the determination of the company's actual acquisition cost by summing market capitalization and net debt, reflecting the business's fundamental foundation and the long-term investor consensus regarding the value of its scientific and technological potential.